ArticleMolecular therapy. Oncology2026
Stem cell-directed targeted chemotherapy primes drug-resistant metastatic ovarian tumors for elimination by natural killer cells.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem-like cells (CSCs) drive ovarian cancer metastasis, therapeutic resistance, and relapse. This study aimed to develop a combination therapeutic strategy capable of eliminating both rapidly proliferating ovarian cancer cells and drug-resistant CSCs, thereby eradicating metastatic disease and preventing relapse. We engineered an adipose-derived mesenchymal stem cell clone (ASC-shCE2:yCD) that homes to tumors and locally converts the prodrugs irinotecan and 5-fluorocytosine (5-FC) into the cytotoxic agents SN38 and 5-fluorouracil (5-FU). This approach was combined with natural killer (NK) cell immunotherapy to eradicate CSCs that survived chemotherapy. Using patient-derived, drug-resistant metastatic ovarian cancer models, we show that exposure to SN38 or 5-FU upregulates NKG2D stress ligands (MICA/B) on CSCs, enhancing their susceptibility to NK-mediated cytotoxicity. Real-time imaging demonstrated rapid homing of engineered adipose-derived stem cells (ASCs) to tumor sites within 3 days. In triple-immunodeficient CIEA NOG mice, ASC-directed enzyme/prodrug therapy followed by NK cell immunotherapy eliminated metastatic ovarian tumors and prevented relapse during the monitoring period. Histopathological and hematological analyses revealed no clinically significant toxicity. Collectively, these findings establish a stem cell-directed chemoimmunotherapy that primes drug-resistant ovarian cancer cells for immune elimination, offering a rationale and effective strategy to safely eradicate metastatic disease and prevent recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.